gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · COYAHealthcarePharmaceuticals

Coya Therapeutics, Inc. Common Stock (COYA)

$3.08−0.96%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$3.11▼ 48.17% in range
Nov 3, 2025Low $3.11 · High $6.51Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Coya Therapeutics closed at $3.08 on Nov 4, down 0.96%, within 0.0% of its 52-week closing low. Volume of 195.4K shares was 1.19× its 20-day average (close to normal).

Split-adjusted performance: -36.5% over one month, -27.4% over six months, -48.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $243.75K, up 49.0% from a year earlier, with a net margin of -2723.4%.

Short interest was 1.3M shares at the Oct 15 settlement, up 5.3% from the prior report (7.2% of float, 8.6 days to cover).

Market cap$72.3M23.5M shares
Revenue · quarter$243.7K+49.0% YoY
Diluted EPS$-0.28—
P/E · TTM—P/S 9.0×
Net margin-2,723.4%Gross 100.0%
Dividend yieldNone
52-week range3.08 – 6.51−52.7% from high
Volume195.4K1.19× 20-day avg
Volatility · 60d56.9%Annualised
Short % of float7.2%8.6 days to cover
Net cash$43.2MCash $43.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −24.1%1M −36.5%3M −32.8%6M −27.4%YTD −46.9%1Y −48.7%3Y −36.4%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum48
Revenue growth78
Net margin10
Value (low P/E)—
Size38

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short1.3M+5.3% vs prior
Days to cover8.6Settled Oct 15
% of float7.2%
Short vol. 10d43.3%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
COYACoya Therapeutics$3.08−0.96%−27.4%+49.0%−2723.4%—$72.3M
MNOVMedicinova$1.45+2.11%0.0%+240.6%−504.8%—$71.4MCompare
PMVPPMV Pharmaceuticals$1.33−3.99%−8.6%———$70.8MCompare
MAIAMAIA Biotechnology$1.14+5.56%−15.6%———$70.4MCompare
ACRVAcrivon Therapeutics$1.74+4.19%−16.7%———$74.6MCompare
LFVNLifevantage Corporation Common Stock (Delaware)$5.97+3.65%−0.5%−23.1%3.0%14.8$75.2MCompare
CRBPCorbus Pharmaceuticals Holdings$3.57−7.75%−67.3%———$69.0MCompare
FTLFFitLife Brands$8.18+3.68%−12.1%+64.6%7.3%12.3$76.8MCompare
TENXTenax Therapeutics$1.81−1.63%−84.9%———$67.7MCompare

News about Coya Therapeutics

All news →
$32 Million Exosome Therapy Market Assessment 2026: Set to Experience Massive Growth, Reaching $1.4 Billion by 2040GlobeNewswire Inc. · Sep 7, 2026▲ Positive

Quick answers

What does Coya Therapeutics do?
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
What is COYA's market cap?
$72.25M, based on the Nov 4 close of $3.08.
Does Coya Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of COYA is sold short?
1.3M shares, 7.2% of float, as of Oct 15, 2026.
What sector is COYA in?
Healthcare, in the Pharmaceuticals industry.

About Coya Therapeutics

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.

HQ: Houston, TX8 employeesListed Dec 29, 2022coyatherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology